Published: 24. August, 2023

US co-development and commercialization partnership signed for CT001 – potential income already from 2024…

  • US co-development and commercialization partnership signed for CT001 – potential income already from 2024
  • Strong clinical progress
    • Pivotal study 0205 recruitment on track – last patient expected Q3-2023
    • Clinical Trial Application (CTA) for study 0202 submitted and under review by competent authorities
  • Post-period event: Loan facility agreement signed to support US launch and strengthening the cash position

 

“During the second quarter of 2023 we were extremely pleased to enter a US partnership with Ventis Pharma to secure the future development and commercialisation of CT001 in the important and large US market. This transformational deal is part of our commercial strategy to leverage the value of our products in different geographical areas and ensure our much-needed solution for pain management in children experiencing acute pain, can reach the patients who need it. At the same time, we continued to build momentum in our clinical development activities, submitting a clinical trial application for our 0202 study. We also look forward to completing patient recruitment in the coming months in our pivotal study with 0205.”  says Jes Trygved, CEO